Clinicopathologic features of Waldenström's macroglobulinemia and marginal zone lymphoma: Are they distinct or the same entity?

Clinical Lymphoma

Volumn 5, Issue 4, 2005, Pages 220-224

  Berger, Françoise ^a,b   Traverse Glehen, Alexandra ^a   Felman, Pascale ^a   Callet Bauchu, Evelyne ^a   Baseggio, Lucille ^a   Gazzo, Sophie ^a   Thieblemont, Catherine ^a   Ffrench, Martine ^a   Magaud, Jean Pierre ^a   Salles, Gilles ^a   Coiffier, Bertrand ^a  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Immunoglobulin M paraproteinemia; Lymphoplasmacytic lymphoma; Trisomy 3

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD27 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; PARAPROTEIN; IMMUNOGLOBULIN M; LEUKOCYTE ANTIGEN;

ANTIBODY PRODUCTION; AUTOIMMUNITY; B CELL LYMPHOMA; BACTERIAL INFECTION; BONE MARROW; CANCER SURVIVAL; CELL DIFFERENTIATION; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL FEATURE; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC TRAIT; HUMAN; IMMUNOCYTOMA; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOMA; LYMPHOPROLIFERATIVE DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MORPHOLOGICAL TRAIT; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NODULAR LYMPHOMATOSIS; NONHUMAN; PATHOGENESIS; PLASMA CELL; PLASMA CELL LEUKEMIA; PLASMACYTOMA; REVIEW; SPLEEN TUMOR; WALDENSTROEM MACROGLOBULINEMIA; CLASSIFICATION; GENETICS; IMMUNOLOGY; MUTATION; PATHOLOGY; PHENOTYPE; SPLEEN; TRISOMY;

ANTIGENS, CD; HUMANS; IMMUNOGLOBULIN M; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; LYMPHOMA, SMALL LYMPHOCYTIC; MUTATION; PHENOTYPE; SPLEEN; TRISOMY; WALDENSTROM MACROGLOBULINEMIA;

EID: 20444441543     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.003     Document Type: Review

References (38)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-1392.
2. Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2001.
3. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:110-115.
4. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95:1950-1956.
5. Lin P, Bueso-Ramos C, Wilson CS, et al. Waldenström's macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients. Am J Surg Pathol 2003; 27:1104-1113.
6. Owen RG. Developing diagnostic criteria in Waldenström's macroglobulinemia. Semin Oncol 2003; 30:196-200.
7. Ghobrial IM, Gertz MA, Fonseca R. Waldenström macroglobulinaemia. Lancet Oncol 2003; 4:679-685.
8. Weng WK, Levy S. Hepatitis C virus (HCV) and lymphomagenesis. Leuk Lymphoma 2003; 44:1113-1120.
9. Pangalis GA, Kyrtsonis MC, Kontopidou FN, et al. Differential diagnosis of Waldenström's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders. Semin Oncol 2003; 30:201-215.
10. San Miguel JF, Vidriales MB, Mateo G, et al. Immunophenotypic analysis of Waldenström's macroglobulinemia. Semin Oncol 2003; 30:187-195.
11. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909-3918.
12. Mansoor A, Medeiros J, Weber DM, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol 2001; 116:543-549.
13. Schop RFJ, Kuehl WM, Van Wier SA, et al. Waldenström's macroglobulinemia neoplastic cells lack IgH translocations but have frequent 6q deletions. Blood 2002; 100:2996-3001.
14. Offit K, Parsa NZ, Filippa D, et al. t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood 1992; 80:2594-2599.
15. Ida S, Rao PH, Nallasivam P, et al. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 1996; 88:4110-4117.
16. Cook JR, Aguilera NI, Reshmi-Skarja S, et al. Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). Hum Pathol 2004; 35:447-454.
17. Avet-Loiseau H, Garand R, Lode L, et al. 14q32 translocations discriminate IgM multiple myeloma from Waldenström's macroglobulinemia. Semin Oncol 2003; 30:153-155.
18. Offit K, Parsa NZ, Gaidano G, et al. 6q deletions define distinct clinico-pathological subsets of non Hodgkin's lymphomas. Blood 1993; 82:2157-2162.
19. Fan YS, Rizkalla K. Comprehensive cytogenetic analysis including multicolor spectral karyotyping and interphase fluorescence in situ hybridization in lymphoma diagnosis. a summary of 154 cases. Cancer Genet Cytogenet 2003; 143:73-79.
20. Sahota SS, Forconi F, Ottensmeier CH, et al. Typical Waldenström macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood 2002; 100:1505-1507.
21. Kriangkum J, Taylor BJ, Treon SP, et al. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004; 104:2134-2142.
22. Martin F, Kearny JF. Marginal-zone B cells. Nat Rev Immunol 2002; 2:2323-2335.
23. Thieblemont C, Felman P, Callet-Bauchu E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003; 4:95-103.
24. Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood 1996; 87:299-307.
25. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004; 4:644-653.
26. Nathwani BN, Drachenberg MR, Hernandez AM, et al. Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma). Semin Hematol 1999; 36:128-138.
27. Berger F. Nodal marginal zone B-cell lymphoma. In: Mauch PM, Armitage JO, Coiffier B, et al, eds. Non-Hodgkin's Lymphomas. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:361-365.
28. Ott MM, Rosenwald A, Katzenberger T, et al. Marginal zone B-cell lymphomas (MZBL) arising at different sites represent different biological entities. Genes Chromosomes Cancer 2000; 28:380-386.
29. Conconi A, Bertoni F, Pedrinis E, et al. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood 2001; 98:781-786.
30. Camacho FI, Algara P, Mollejo M, et al. Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. Am J Surg Pathol 2003; 2:762-771.
31. Marasca R, Vaccari P, Luppi M, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 2001; 159:253-261.
32. Mateo M, Mollejo M, Villuendas R, et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol 1999; 154:1583-1589.
33. Gazzo S, Baseggio L, Coignet L, et al. Cytogenetic and molecular delineation of a region of chromosome 3 commonly gained in marginal zone B-cell lymphoma. Haematologica 2003; 88:31-38.
34. Hernandez JM, Garcia JL, Gutierrez NC, et al. Novel genomic imbalances in B cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol 2001; 158:1843-1850.
35. Algara P, Mateo MS, Sanchez-Beato M, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002; 99:1299-1304.
36. Bahler DW, Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas appear to originate from different B cell types. Am J Pathol 2002; 161:81-88.
37. Miranda RN, Cousar JB, Hammer RD, et al. Somatic mutation analysis of IgH variable regions reveals that tumor cells of most parafollicular (monocytoid) B-cell lymphoma, splenic marginal zone B-cell lymphoma, and some hairy cell leukemia are composed of memory B lymphocytes. Hum Pathol 1999; 30:306-312.
38. Zhu D, Orchard J, Oscier DG, et al. V(H) gene analysis of splenic marginal zone lymphomas reveals diversity in mutational status and initiation of somatic mutation in vivo. Blood 2002; 100:2659-2661.